Vivos INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
RDGL
Vivos INCVivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, bolstering its leadership in targeted cancer therapies.
OQB
RDGL
Vivos INCVivos Inc. announced the appointment of Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, strengthening its leadership in targeted cancer therapies.
OQB
RDGL
Vivos INCVivos Inc. announced the creation of Vivos Scientific India LLP, a wholly owned entity aimed at establishing manufacturing, expanding human therapies, and pursuing commercialization in India.
OQB
RDGL
Vivos INCVivos Inc. reports positive initial safety results and early signs of efficacy from its RadioGel Precision Radionuclide Therapy human clinical trials, leading to plans for trial expansion.
OQB
RDGL
Vivos INCVivos Inc. finalized the sale of 12,500,000 shares of common stock for $1.5 million and issued warrants to purchase 6,250,000 shares.
OQB
RDGL
Vivos INC8-K: Vivos Inc. Files Application for Human Clinical Trials of Radiogel Precision Radionuclide Therapy
Vivos Inc. has submitted an application to the FDA for an Investigational Device Exemption to begin human clinical trials of its Radiogel Precision Radionuclide Therapy.
OQB
RDGL
Vivos INCVivos Inc. has renewed its employment agreement with CEO Michael Korenko, extending his term for two years with an increased base salary, stock grants, and potential bonuses.